Amneal Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AMRX Nasdaq 2830 www.amneal.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Amneal Pharmaceuticals, Inc.

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults - May 15th, 2025 12:00 pm
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S. - May 8th, 2025 11:00 am
Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ... - May 3rd, 2025 7:03 am
Amneal Reports First Quarter 2025 Financial Results - May 2nd, 2025 10:00 am
Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years - Apr 17th, 2025 11:37 am
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month - Apr 11th, 2025 12:00 pm
Amneal to Report First Quarter 2025 Results on May 2, 2025 - Apr 8th, 2025 8:05 pm
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease - Apr 7th, 2025 12:00 pm
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S. - Apr 3rd, 2025 12:00 pm
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - Apr 1st, 2025 12:00 pm
Amneal to Participate at Upcoming Investor Conference - Mar 10th, 2025 8:05 pm
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA - Mar 3rd, 2025 9:05 pm
Amneal Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations - Mar 1st, 2025 2:10 pm
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results - Feb 28th, 2025 11:00 am
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide - Feb 19th, 2025 1:00 pm
Although Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stake - Feb 13th, 2025 10:53 am
7MM PD market to grow by $4.5bn between 2023 and 2033 - Jan 30th, 2025 11:22 am
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 - Jan 29th, 2025 1:30 pm
Kashiv Biosciences’ Phase I trial of KSHB002 injection meets primary endpoints - Jan 29th, 2025 12:25 pm
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin - Jan 23rd, 2025 1:00 pm